The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Following the success of daratumumab, a range of other anti-CD38 antibodies are being investigated for multiple myeloma (MM). Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses three new such antibodies: isatuximab, MOR202 and TAK-079. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
